华东医药：子公司玛比嗪注射液获药品注册证书

Core Viewpoint - Huadong Medicine (000963) announced the approval of its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., for the marketing authorization of Remabizine Injection by the National Medical Products Administration [1] Group 1: Company Developments - The approved drug, Remabizine Injection, is an exogenous fluorescent tracer used in conjunction with MediBeacon Inc.'s transcutaneous glomerular filtration rate measurement device [1] - The purpose of the drug is to evaluate patients' glomerular filtration rate (GFR) [1]